New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 28, 2012
08:30 EDTCRIS, RHHBYCuris licenses worldwide development, commercialization rights for IAP Inhibitor
Curis (CRIS) announced that it has licensed from Genentech, a member of the Roche Group, (RHHBY), exclusive, worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins. Genentech has recently completed a Phase I clinical trial of GDC-0917, in which 42 people received daily oral doses of GDC-0917 for two weeks, followed by a one week rest period. This 21-day cycle is repeated until disease progression or study discontinuation for any other reason. The primary endpoints of the study include evaluating the safety and tolerability and the pharmacokinetics of GDC-0917 in people with solid tumors or lymphoma and determining the maximum-tolerated-dose and a potential recommended dose for further clinical studies. Secondary endpoints include a preliminary assessment of anti-tumor activity of GDC-0917 and evaluating pharmacodynamic markers. Genentech plans to present full study results at a medical conference in mid-2013, Curis said.
News For CRIS;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
11:14 EDTRHHBYRoche unit announces collaboration pact with ImmunoGen
Ventana Medical Systems, a member of the Roche Group (RHHBY), announced it has entered into an agreement with ImmunoGen (IMGN) to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha, or FRa, that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate.
07:21 EDTCRISCuris announces allowance of U.S. patent
Curis announced the receipt of a Notice of Allowance of a U.S. patent that covers a broad genus of compounds that target histone deacetylase, or HDAC, and phosphoinositide 3-kinase, or PI3K, activities in a single chemical structure including CUDC-907, Curis' oral, dual HDAC and PI3K small molecule inhibitor that is currently being studied in Phase 1 clinical trials. This patent, along with prior patents issued to Curis, further strengthens the Company's intellectual property portfolio of compounds including CUDC-907 that inhibit HDAC and PI3K enzymes in a single small molecule for the treatment of certain human diseases. Collectively, these patents generically cover composition-of-matter and methods of use of CUDC-907 as well as a broad range of proprietary chemical entities that target HDAC and PI3K enzymes, and in some instances mammalian target of rapamycin, within a single molecule for the treatment of certain human diseases.
October 27, 2014
20:54 EDTRHHBYLeerink's major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
07:20 EDTRHHBYAmerican Association of Blood Banks to hold annual meeting
Subscribe for More Information
October 24, 2014
12:03 EDTRHHBYRoche reports CHMP recommends label update for Esbriet
Subscribe for More Information
October 21, 2014
07:15 EDTRHHBYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
12:37 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
07:19 EDTRHHBYIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTRHHBYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTRHHBYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use